The incoming changes to hemp classification in the US are already facing major issues, with the Government’s own Congressional Research Service (CRS) stating that it remains ‘unclear’ how it will be enforced in practice.
The new rules will be implemented in a little over a month. They are likely to impact both the hemp industrial and the hemp for consumption industries. However, some advocates warn that these restrictions could decimate the US seed and genetics markets.
The report notes that both the Food and Drug Administration and Drug Enforcement Administration ‘may lack the resources to broadly enforce the laws prohibiting intoxicating hemp products on the market,’ leading to questions over whether the ban will mirror the federal government’s hands-off approach to state-legal marijuana.
The CRS highlights critical concerns with the legislation
In a CRS analysis published earlier this month (December 03), the agency highlights potential parallels to the state enforcement of cannabis, noting that despite cannabis remaining federally illegal as a Schedule I controlled substance, ‘the federal response has largely been to allow states to implement their own marijuana laws despite the fact that state-regulated activities may violate the Controlled Substances Act.’
If intoxicating hemp products persist after November 13, 2026, when the new definition takes effect, they ‘could be subject to the same criminal and collateral issues as marijuana,’ the report noted.
The likelihood that this will be enforced is still unclear.
FDA is required to publish list of THC-class and naturally-occurring cannabinoids as well as cannabinoids having THC-like effect within 90-days of its enactment. The deadline for this publication falls mid-February, 2026. The agency must also define the term ‘container’ for purposes of the 0.4 milligram per-container limit.
However, the CRS says it ‘remains to be seen’ whether FDA will pursue enforcement actions beyond these administrative requirements.
The report highlights that both the Food and Drug Administration and Drug Enforcement Administration ‘may lack the resources to broadly enforce the laws prohibiting intoxicating hemp products on the market, particularly given the scale of the industry and the complexity of distinguishing compliant from non-compliant products.
The nonpartisan research agency, which serves as shared staff to congressional committees and members of Congress, added that the FDA and DEA, ‘in coordination with the Department of Justice, have a range of civil and criminal remedies they may use in efforts to exercise control over these activities,’ but stopped short of predicting which enforcement mechanisms might be deployed.
Furthermore, it suggests Congress ‘may choose to exercise oversight over federal enforcement priorities regarding state-regulated cannabis activities, suggesting potential political pressure on how aggressively agencies pursue violations.
The incoming changes to hemp classification in the US are already facing major issues, with the Government’s own Congressional Research Service (CRS) stating that it remains ‘unclear’ how it will be enforced in practice.
Advocates warn that with a year left before new regulations are implemented, they will have major consequences for the intoxicating and industrial hemp industries. They also say the restrictions are likely to decimate the US seeds and genetics industry.
The report notes that both the Food and Drug Administration and Drug Enforcement Administration ‘may lack the resources to broadly enforce the laws prohibiting intoxicating hemp products on the market,’ leading to questions over whether the ban will mirror the federal government’s hands-off approach to state-legal marijuana.
The CRS highlights critical concerns with the legislation
In a CRS analysis published earlier this month (December 03), the agency highlights potential parallels to the state enforcement of cannabis, noting that despite cannabis remaining federally illegal as a Schedule I controlled substance, ‘the federal response has largely been to allow states to implement their own marijuana laws despite the fact that state-regulated activities may violate the Controlled Substances Act.’
If intoxicating hemp products persist after November 13, 2026, when the new definition takes effect, they ‘could be subject to the same criminal and collateral issues as marijuana,’ the report noted.
The likelihood that this will be enforced is still unclear.
FDA must publish lists of cannabinoids that are naturally occurring, cannabinoids of the THC class, and cannabinoids which have THC like effects, within 90 days after enactment. This deadline falls in February 2026. The agency must also define the term ‘container’ for purposes of the 0.4 milligram per-container limit.
However, the CRS says it ‘remains to be seen’ whether FDA will pursue enforcement actions beyond these administrative requirements.
The report highlights that both the Food and Drug Administration and Drug Enforcement Administration ‘may lack the resources to broadly enforce the laws prohibiting intoxicating hemp products on the market, particularly given the scale of the industry and the complexity of distinguishing compliant from non-compliant products.
The nonpartisan research agency, which serves as shared staff to congressional committees and members of Congress, added that the FDA and DEA, ‘in coordination with the Department of Justice, have a range of civil and criminal remedies they may use in efforts to exercise control over these activities,’ but stopped short of predicting which enforcement mechanisms might be deployed.
Furthermore, it suggests Congress ‘may choose to exercise oversight over federal enforcement priorities regarding state-regulated cannabis activities, suggesting potential political pressure on how aggressively agencies pursue violations.
Cannabis Law Resources in Poland
Discover essential legal information about the cultivation of cannabis, its sale, and regulations governing medical products in Poland. These guides will help you understand the legal requirements, such as certifications and permissions.
-
Polish News Registration and Interests of Cannabis Businesses
-
Permissions for Cannabis Sales in Poland
-
Authorization for Importing or Manufacturing Medical Products
-
Permission for Manufacturing or Importing Medical Products
-
Certificate of Good Manufacturing Practices (GMP)
-
Registration of Medical Products in Poland